Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
174
resultados
Última actualización
25/04/2026 [09:14:00]
Resumen de: US20260108568A1
0000 Provided are a Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease and a use thereof, and the Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease is named as Bifidobacterium longum subsp. infantis BI03 strain, with a deposit number of CGMCC No. 24473 and deposit date of Mar. 7, 2022. The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.
Resumen de: US20260108494A1
0000 The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) wherein each symbol is as defined in the description or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.
0000
Resumen de: WO2026085129A1
Provided herein are compositions and methods for treating or preventing neurodegenerative disease and for treating or preventing symptoms associated with neurodegenerative disease, including Parkinson's disease. For example, provided are methods of treating a patient with Parkinson's disease, the method comprising administering to the patient vectors comprising a nucleic acid encoding glutamic acid decarboxylase (GAD).
Resumen de: WO2026082108A1
The present invention relates to use of an NLRP3 inhibitor for treating Parkinson's disease or Parkinsonism. Specifically, the present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating Parkinson's disease or Parkinsonism, wherein each substituent is as defined in the specification.
Resumen de: DE102024130715A1
Die vorliegende Offenbarung bezieht sich auf eine pflanzliche Mundspüllösung, die Ruta graveolens und Saxifraga enthält und speziell zur Vorbeugung von neurologischen Erkrankungen wie Parkinson, Alzheimer, Lähmungen und Nervenschäden entwickelt wurde. Verfahren zur Herstellung der pflanzlichen Mundspüllösung durch Einweichen einer fein gemahlenen Mischung aus Ruta graveolens und Saxifraga in Alkohol. Die resultierende Lösung wird als Mundspülung verabreicht und zum Spülen und Gurgeln verwendet. Die Erfindung bietet eine wirksame, natürliche therapeutische Alternative zur Behandlung neurodegenerativer Erkrankungen, zur Förderung des Neuroschutzes und zur möglichen Unterstützung der Regeneration geschädigter Nervenzellen.
Resumen de: WO2026082004A1
The present invention relates to a fused heteroaryl derivative, a preparation method therefor, and an application thereof. The fused heteroaryl derivative can be used in a sodium channel inhibitor, and/or in a GABA receptor agonist, or in treating neuropsychiatric disorders such as epilepsy, Parkinson's, schizophrenia, or depression.
Resumen de: AU2024342582A1
The present disclosure provides antibodies that specifically bind to human TDP-43 and methods of using these antibodies to treat patients with TDP-43-related diseases, including Amyotrophic Lateral Sclerosis (ALS).
Resumen de: WO2026085233A1
The disclosure relates to formulations of double stranded ribonucleic acid (dsRNAi) agents targeting a MAPT gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated neurodegenerative disease or disorder, e.g., Alzheimer's disease, FTD, PSP, or other tauopathy, using such dsRNAi agent formulations.
Resumen de: WO2026081146A1
A composition containing a brain protein hydrolysate, a preparation method, and a use. The composition comprises the following raw materials: porcine brain protein hydrolysate, deer brain protein hydrolysate, bovine collagen peptide powder, Gastrodia elata powder, sea buckthorn powder, hawthorn powder, chicken gizzard membrane powder, vitamin C, vitamin B1, vitamin B3, vitamin B5, vitamin B6, and vitamin B12. The composition has anti-inflammatory and antioxidant effects, and can also be used for preparing a medicament for preventing Alzheimer's disease.
Resumen de: WO2026082154A1
Deposition of N-terminally truncated and pyroglutamate-modified Abeta peptides (AβpE3) play an important role in the aggregation of the amyloid-β (Aβ) protein in the brain. The N-terminally truncated and pyroglutamate-modified Abeta peptides, therefore, can be a suitable target for the prevention and treatment of Alzheimer's Disease (AD). Disclosed herein are antibodies and fragments having excellent specificity to N-terminally truncated and pyroglutamate-modified Abeta peptides, as well as uses of these antibodies and fragments for the prevention and treatment of AD.
Resumen de: US20260108572A1
0000 The objective of the present invention is to provide an Alzheimer-type dementia suppressant that is safe and thus can be administered daily and utilized as a health food and by which Alzheimer-type dementia can be suppressed, and a method for producing the Alzheimer-type dementia suppressant. In addition, the objective of the present invention is also to provide a use of an aboveground part of Sesamum indicum or an extract thereof for suppressing Alzheimer-type dementia, and a method for suppressing Alzheimer-type dementia. The Alzheimer-type dementia suppressant according to the present invention is characterized in comprising an aboveground part of Sesamum indicum or an extract thereof as an active ingredient.
Resumen de: AU2024357688A1
This invention relates to the treatment of a neuropsychiatric disorder, such as schizophrenia or Parkinson's disease, by administration (for example, transdermally) of tilivapram, zatolmilast, roflumilast, or a pharmaceutically acceptable salt thereof.
Resumen de: WO2026085535A2
Disclosed is a method for treating for treating pathologies associated with Down syndrome (e.g., symptoms of Alzheimer's disease and metabolic abnormalities), preventing the onset of pathologies associated with Down syndrome in patients with Down syndrome, reducing cognitive or functional decline, or reducing symptom load in a subject having Down Syndrome, in need or at risk thereof, comprising administering to said subject a therapeutically effective amount of an anti-Follicle Stimulating Hormone (FSH) antibody, or an antigen-binding portion thereof.
Resumen de: WO2024260959A1
The present invention relates to an improved process for preparing optically active secondary amines, or a pharmaceutically or veterinary acceptable salt thereof, in high yield and high purity involving (2-naphthoyl)-L-proline as chiral resolving agent. The invention also relates to the use of (2-naphthoyl)-L-proline as chiral resolving agent of secondary amines, preferably of amine compounds of formula (I), wherein R1 is H, C1- C4 alkyl, preferably R1 is methyl; and R2 is C1-C4 alkyl, preferably R2 is n-propyl and the use of the obtained optically amine compounds of formula (IV) for the preparation of rotigotine.
Resumen de: EP4729620A1
Provided are a gene therapy vector for treating Parkinson's disease and a use thereof. Specifically, provided is an adeno-associated virus (AAV) vector for treating Parkinson's disease, which can simultaneously express functional tyrosine hydroxylase (TH), GTP-cyclohydrolase 1 (GCH1) and aromatic amino acid decarboxylase (AADC) to promote dopamine synthesis. Also provided are an AAV virus particle containing the AAV vector, a composition containing the AAV vector or the AAV virus particle, and uses of the AAV vector, the AAV virus particle and the composition in the preparation of drugs for preventing or treating Parkinson's disease.
Resumen de: WO2026077485A1
The present invention relates to an application of a DFNA5/GSDME inhibitor in preparing a drug for treating Alzheimer's disease. Also provided is an application of a specific DFNA5 gene knockdown system in preparing a drug for treating Alzheimer's disease. The present invention demonstrates that in reactive astrocytes of patients with Alzheimer's disease, the mRNA expression level of GSDME is significantly high, and GSDME can be used as an effective target for Alzheimer's disease. Provided is an application of a reagent, which specifically inhibits GSDME gene expression in astrocytes, in preparing a drug for treating Alzheimer's disease, so as to develop a novel treatment drug for Alzheimer's disease. The present invention demonstrates that the reagent, which inhibits GSDME gene expression, can be used for preparing a drug for treating Alzheimer's disease. The present invention also provides a theoretical basis for clinical treatment of Alzheimer's disease.
Resumen de: WO2026077192A1
Provided in the present invention are preparation and use of a novel MAO-B inhibitor containing a tetralin-1-amine structure, which belong to the field of medicines. The derivative is a compound represented by formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The compound of the present invention can be used for inhibiting monoamine oxidase (MAO), especially selectively inhibiting MAO-B. The compound can be used for treating diseases such as Parkinson's disease, Alzheimer's disease, and emotional disorders, and exhibits good application prospects.
Resumen de: WO2026079761A1
The present invention relates to a composition for alleviating, preventing, or treating Alzheimer's disease, the composition comprising apigenin and oxyresveratrol. A composition according to the present invention is highly effective in reducing Alzheimer's disease pathology caused by β-amyloid, which is increased by aging and oxidative stress, and improving β-amyloid-induced memory loss and cognitive function.
Resumen de: US20260103445A1
The present invention relates to compositions comprising an RXR agonist, an RAR agonist, or a dual RXR/RAR agonist. The present invention further relates to methods of using the agonist compositions for treating or preventing dementia and cancer. In some embodiments, the dementia comprises Alzheimer's disease. In some embodiments, the cancer comprises leukemia.
Resumen de: WO2026077393A1
The present invention belongs to the field of biopharmaceuticals. Disclosed are a Muse cell-derived protein complex, a preparation method therefor, and use thereof. The composition of the protein complex is: a stem cell lysate of Muse cells after being cultured in a stress environment for a predetermined time, or a protein complex obtained by separating and purifying the stem cell lysate. The protein complex has a good cell damage repair effect, especially a strong ability to repair nerve cell damage, and is expected to be used for treating neurodegenerative diseases, cerebral stroke, cerebrovascular disease, arthritis, enteritis, recovery after trauma, autism, depression, and pulmonary fibrosis. In particular, the neurodegenerative diseases include, but are not limited to, Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and different types of spinocerebellar ataxia (SCA).
Resumen de: AU2024354107A1
Provided are an siRNA inhibiting the expression of an amyloid precursor protein (APP) gene in a human cell, a polypeptide-oligonucleotide drug, and a use. The siRNA has good APP expression inhibitory activity, and a suitable modification is made to the siRNA to improve the silencing capability against a target and reduce off-target activity. The siRNA and a conjugate thereof are expected to be applied for clinically preventing and treating an APP target-related disease such as cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).
Resumen de: US20260103474A1
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: WO2026077862A1
The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.
Resumen de: WO2026077861A1
The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.
Nº publicación: WO2026080811A1 16/04/2026
Solicitante:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
Resumen de: WO2026080811A1
Provided are methods and compositions for treating Parkinson's disease (PD). The compositions inhibit the expression or activity of adenosylmethionine decarboxylase 1 (AMD1).
BOPI
Sede Electrónica
